REGN17372+Linvoseltamab
PreclinicalMonoclonal antibody
RegeneronREGN17372+Linvoseltamab is one of 2 small molecule programs targeting Relapsed Refractory Multiple Myeloma (RRMM). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Relapsed Refractory Multiple Myeloma (RRMM)
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed Refractory Multiple Myeloma (RRMM)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for REGN17372+Linvoseltamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]